Deciphera Pharmaceuticals Llc Stock Price To Sales
Deciphera Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Deciphera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Deciphera Stock. The fundamental analysis module provides a way to measure Deciphera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Deciphera Pharmaceuticals stock.
Deciphera |
Deciphera Pharmaceuticals LLC Company Price To Sales Analysis
Deciphera Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Deciphera Pharmaceuticals Price To Sales | 12.65 X |
Most of Deciphera Pharmaceuticals' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Deciphera Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Deciphera Pharmaceuticals LLC has a Price To Sales of 12.6518 times. This is 40.88% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to sales for all United States stocks is 10.79% lower than that of the firm.
Deciphera Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Deciphera Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Deciphera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics of similar companies.Deciphera Pharmaceuticals is currently under evaluation in price to sales category among its peers.
Deciphera Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X | |||
| Price To Book | 7.00 X | |||
| Price To Sales | 12.65 X | |||
| Revenue | 163.36 M | |||
| Gross Profit | (62.55 M) | |||
| EBITDA | (210.96 M) | |||
| Net Income | (194.94 M) | |||
| Cash And Equivalents | 383.85 M | |||
| Cash Per Share | 5.74 X | |||
| Total Debt | 25.88 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.02 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (146.7 M) | |||
| Short Ratio | 1.05 X | |||
| Earnings Per Share | (2.21) X | |||
| Price To Earnings To Growth | (0.32) X | |||
| Target Price | 27.52 | |||
| Number Of Employees | 355 | |||
| Beta | 0.18 | |||
| Market Capitalization | 2.21 B | |||
| Total Asset | 473.57 M | |||
| Retained Earnings | (1.43 B) | |||
| Working Capital | 280.82 M | |||
| Current Asset | 70.55 M | |||
| Current Liabilities | 5.98 M | |||
| Net Asset | 473.57 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Correlations Find global opportunities by holding instruments from different markets |